

for young men and 15 to 28 mEq/day for women. This suggests that the average diet is at borderline levels for maintenance of magnesium levels in healthy adults. Magnesium is ubiquitous in our diet and is especially abundant in green vegetables rich in chlorophyll (a chelator of magnesium), as well as in seafood, grains, nuts, and meats (2). Under normal circumstances, the GI tract and kidney closely maintain magnesium balance. Normal serum magnesium concentrations range between 1.5 and 2.3 mEq/L (0.75 to 1.15 mmol/L) in healthy subjects, with a variation between the different laboratories. Serum levels of 1.7 mEq/L usually indicate magnesium deficiency (1,2,3). Only about 1% to 2% of the 21 to 28 g (1,750 to 2,400 mEq) of magnesium present in the adult human body is in the extracellular fluid (ECF) compartment (3). The principal cellular stores of magnesium in the body are bone (67%) and muscle (20%). The status of body magnesium balance and particularly ECF magnesium concentration is largely determined by the renal excretion of magnesium (15). Unlike most cations, the loop of Henle is the major site of magnesium reabsorption. Magnesium concentration in the early distal tubular fluid is only 60% to 70% of the ultrafiltrable magnesium concentration, suggesting that some 50% to 60% of the filtered magnesium is reabsorbed in the loop of Henle, primarily in the thick ascending limb (TAL). In the distal convoluted tubule, fine-tuning of magnesium reabsorption occurs (16).

The first description of symptoms related to hypomagnesemia was in 1960 when Vallee et al. (17) described five patients with hypomagnesemia and symptoms and signs that are now felt to be classic for magnesium deficiency. Magnesium deficiency may be caused by decreased intake or intestinal absorption, increased losses via the GI tract, kidneys, or skin, and rarely, by sequestration in the bone compartment (18). The acquired forms of renal magnesium wasting are largely drug induced. Renal magnesium wasting has been well documented in a number of patients receiving drugs, virtually all diuretics (19). Recently, proton pump inhibitors (PPIs) have been reported to cause hypomagnesemia in some patients. The evidence suggests that it is due to intestinal Mg malabsorption (20). Loop diuretics inhibit the apical membrane NaK2Cl cotransporter of the TAL and abolish the transepithelial potential difference, thereby inhibiting paracellular Mg reabsorption. (21). Long-term treatment with thiazide diuretics, which inhibit the NaCl cotransporter (NCC), also cause renal Mg wasting. Thiazide diuretics caused downregulation of expression of TRPM6, the apical Mg entry channel in the distal convoluted tubule (DCT), which may explain the mechanism of the magnesuria (22). Kroenke et al. in their similar study found no difference in serum magnesium levels between the diuretic users and nondiuretic users, reporting a rate of 10% in the diuretic group. They stated that they found no difference due to the generally low doses of diuretics used as antihypertensive agents, and the use of drugs such as thiazide diuretics which cause hypomagnesemia in higher doses (23). Dose may be an important factor. In an early study (24) suggesting thiazide-induced hypomagnesemia, high doses (100 to 150 mg) of hydrochlorothiazide were used, and an inverse relationship between serum magnesium levels and hydrochlorothiazide dose over the entire range of 12.5 to

200 mg was recently reported (25). However also in our study, hypomagnesemia prevalence was 7.1% in the diuretic group and 6.8% in the nondiuretic group in the total group of patients, with no significant difference. In our patient group, the diuretic drug was generally in combination with ACE or ARB, with a dosage of 12.5 mg. This suggests that the thiazide diuretics at these dose ranges do not contribute to the hypomagnesemia in hypertensive patients.

It is observed that the only significantly correlated electrolyte with the presence of hypomagnesemia is potassium in the patients that use diuretic combinations in our study. A mild hypokalemia tendency was observed in the diuretic group. While some studies have suggested a frequent association between deficiencies of these two cations (26), others have noted a poor correlation (27). Studies showing a good correlation have often involved hospitalized patients in whom the prevalence of both hypokalemia and hypomagnesemia is much higher than in ambulatory patients and in whom other factors contributing to the depletion of these two cations, such as alcoholism malnutrition, and heart failure, are commonly present. Tissue levels of potassium and magnesium may show a better correlation than serum levels (28,29).

According to our results, the use of PPIs in combination with antihypertensive agents including diuretics increase the frequency of hypomagnesemia. Hypomagnesemia has been described usually in case reports with the chronic use of omeprazole (usually for more than one year) and PPIs [30-31]. The association of PPIs with lower serum magnesium has also been described in population studies. The best data come from a large cohort of 11,490 patients admitted to the intensive care unit at a single center (32). In this study, the relationship between PPI use and magnesium varied by whether patients concurrently used diuretics. The presumed mechanism is impaired absorption of magnesium by intestinal epithelial cells caused by PPI-induced inhibition of transient receptor potential melastatin-6 (TRPM6) and TRPM7 channels [33]. Renal losses are not likely to be involved since urinary magnesium excretion is appropriately low in patients with hypomagnesemia due to PPIs (34).

In March 2011, the United States Food and Drug Administration (FDA) issued a safety warning suggesting that, in patients expected to be on PPIs for long periods of time and in those taking other medications associated with hypomagnesemia as described below (eg, diuretics), providers should measure the serum magnesium levels prior to initiation of PPI therapy and also periodically during the treatment (35).

Magnesium may influence blood pressure by modulating vascular tone and structure through its effects on myriad biochemical reactions that control vascular contraction/dilation, growth/apoptosis, differentiation and inflammation. Magnesium acts as a calcium channel antagonist, it stimulates production of vasodilator prostacyclins and nitric oxide and it alters vascular responses to vasoconstrictor agents. (36) Alterations in some of these systems may contribute to hypomagnesemia and susceptibility for hypertension or decreased antihypertensive drug response. Magnesium therapy can prevent the

development of resistant hypertension and arrhythmias in hypertensives with diuretic-induced hypomagnesemia. It might also reduce blood pressure at least up to 10/5 mm Hg provided adequate magnesium salts are given for an adequate period of time (37). The prevalence of prehypertension(preHTN) in adult population is 37.5%, and hypomagnesemia is strongly associated with preHTN(38). In accordance with these results, we evaluated the relationship between the number of the antihypertensive drugs and hypomagnesemia presence. Our results show that, in both diuretic and nondiuretic groups, there was statistically no significant difference between the number of the hypertensive agents and the frequency of hypomagnesemia ($p>0,05$). It seems that presence of hypomagnesemia doesn't affect drug numbers that needs to control hypertension. But we need more study about this subject.

In summary, in ambulatory hypertensive patients which use diuretic and nondiuretic antihypertensive combinations, there was statistically no significant difference in hypomagnesemia frequency. Routine measurement of serum magnesium proved unrewarding in these group of patients. Except in patients receiving high-dose thiazides and loop diuretics, the prevalence of hypomagnesemia may be higher. Serum magnesium determinations might be reserved for selected circumstances, when other factors potentiating magnesium deficiency are present; such as patients with nutritional problems and low dietary intake, gastrointestinal losses, renal losses and PPIs usage. Therefore, in patients with uncomplicated hypertension, if there is no symptom regarded with hypomagnesemia, routine serum magnesium determination seems unnecessary.

References

- [1] Brunette MG, Vigneault N, Carriere S. Micropuncture study of renal magnesium transport in magnesium-loaded rats. *Am J Physiol.* 1975;229: 1695
- [2] 432. Massry SG, Coburn JW, Kleeman CR. Renal handling of magnesium in the dog. *Am J Physiol.* 1969;216: 1460.
- [3] Schrier, Robert W.; Coffman, Thomas M.; Falk, Ronald J.; Molitoris, Bruce A.; Neilson, Eric G. (2013-02-06). *Schrier's Diseases of the Kidney (Kindle Locations 106379-106380)*. LWW. Kindle Edition.
- [4] Seller RH, Ramirez-Muxo O, Brest AN, et al: Magnesium metabolism in hypertension. *JAMA* 1965;191:118-120.
- [5] Ryan MP, Devane J, Ryan MF, et al: Effects of diuretics on the renal handling of magnesium. *Drugs* 1984;28(suppl 1):167-181.
- [6] Leary WP, Reyes AJ: Diuretic-induced magnesium losses. *Drugs* 1984;28(suppl 1):183-186.
- [7] Eknoyan G, Suki WN, Martinez-Maldonado M: Effects of diuretics on urinary excretion of phosphate, calcium, and magnesium. *J Clin Lab Med* 1970;76:257-266.
- [8] Sherwood RA, Aryanayagam P, Rocks BF, et al: Hypomagnesemia in the elderly. *Gerontology* 1986;32:105-109.
- [9] Smith WO, Kyriakopoulos AA, Hammarsten JF: Magnesium depletion induced by various diuretics. *J Okla State Med Assoc* 1962;55:248-250.
- [10] Hollifield JW: Thiazide treatment of hypertension: Effects of thiazide diuretics on serum potassium, magnesium, and ventricular ectopy. *Am J Med* 1986;80(suppl 4A):8-12.
- [11] Burch GE, Giles TD: The importance of magnesium deficiency in cardiovascular disease. *Am Heart J* 1977;94:649-657.
- [12] Seelig MS: *Magnesium Deficiency in the Pathogenesis of Disease*. New York, Plenum Publishing Corp, 1980, pp 219-252, 358-370.
- [13] Martin HE: Clinical magnesium deficiency. *Ann NY AcadSci* 1969;162:891-900.
- [14] Calcium, magnesium, and diuretics. *Br Med J* 1975;1:170-171.
- [15] Aikawa JK, Rhoades EL, Gordon GS. Urinary and fecal excretion of orally administered Mg²⁺. *Proc Soc Exp Biol Med.* 1958;98: 29.
- [16] 534. Quamme GA, Dirks JH. Intraluminal and contraluminal magnesium on magnesium and calcium transfer in the rat nephron. *Am J Physiol.* 1980;238: F187-F198.
- [17] Wester PO, Dyckner T: Diuretic treatment and magnesium losses. *Acta Med Scand* 1981;647:147-152.
- [18] 206. Sutton R.A., Domrongkitchaiporn S. Abnormal renal magnesium handling. *Miner Electrolyte Metab.* 1993;19(4-5):232-240.
- [19] Dyckner T, Webster PO. Ventricular extrasystoles and intracellular electrolytes before and after potassium and magnesium infusions in patients on diuretic therapy. *Am Heart J.* 1979;97: 12.
- [20] 207. Elisaf M., Panteli K., Theodorou J., et al. Fractional excretion of magnesium in normal subjects and in patients with hypomagnesemia. *Magnes Res.* 1997;10(4):315-320.
- [21] Dyckner T., Wester P.O. Renal excretion of electrolytes in patients on long-term diuretic therapy for arterial hypertension and/or congestive heart failure. *Acta Med Scand.* 1985;218(5):443-448.
- [22] Arnaud M.J. Update on the assessment of magnesium status. *Br J Nutr.* 2008;99(suppl 3):S24-S36.
- [23] Kroenke K, Wood DR, Hanley JF. The value of serum magnesium determination in hypertensive patients receiving diuretics. *Arch Intern Med.* 1987 Sep;147(9):1553-6.
- [24] Seller RH, Ramirez-Muxo O, Brest AN, et al: Magnesium metabolism in hypertension. *JAMA* 1965;191:118-120.
- [25] Hollifield JW: Thiazide treatment of hypertension: Effects of thiazide diuretics on serum potassium, magnesium, and ventricular ectopy. *Am J Med* 1986;80(suppl 4A):8-12.
- [26] Whang R, Oei TO, Aikawa JK, et al: Predictors of clinical hypomagnesemia: Hypokalemia, hypophosphatemia, hyponatremia, and hypocalcemia. *Arch Intern Med* 1984;144:1794-1796
- [27] Whang R, Chrysant S, Dillard B, et al: Hypomagnesemia and hypokalemia in 1000 treated ambulatory hypertensive patients. *J Am Coll Nutr* 1982;1:317-322.
- [28] Dyckner T, Wester PO: The relation between extra- and intracellular electrolytes in patients with hypokalemia and/or diuretic treatment. *Acta Med Scand* 1978;204:269-282.
- [29] Dyckner T, Wester PO: Intracellular magnesium loss

after diuretic administration. *Drugs* 1984;28(suppl 1):161-166.

- [30] Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. *Aliment Pharmacol Ther.* 2012 Sep;36(5):405-13. Epub 2012 Jul 4.
- [31] Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. *Clin Endocrinol (Oxf).* 2008;69(2):338
- [32] Danziger J, William JH, Scott DJ, Lee J, Lehman LW, Mark RG, Howell MD, Celi LA, Mukamal KJ. Proton-pump inhibitor use is associated with low serum magnesium concentrations. *Kidney Int.* 2013 Apr;83(4):692-9. Epub 2013 Jan 16.
- [33] Perazella MA. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. *Kidney Int.* 2013 Apr;83(4):553-6.
- [34] Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. *Ann Intern Med.* 2009;151(10):755.
- [35] <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245275.htm> (Accessed on March 08, 2011).
- [36] Yogi A¹, Callera GE, Antunes TT, Tostes RC, Touyz RM. Vascular biology of magnesium and its transporters in hypertension. *Magnes Res.* 2010 Dec;23(4):S207-15. doi: 10.1684/mrh.2010.0222. Epub 2011 Jan 4.
- [37] Singh RB¹, Rastogi SS, Mehta PJ, Cameron EA. Magnesium metabolism in essential hypertension. *Acta Cardiol.* 1989;44(4):313-22.
- [38] Rodríguez-Moran M, Guerrero-Romero F. Hypomagnesemia and prehypertension in otherwise healthy individuals. *Eur J Intern Med.* 2014 Feb;25(2):128-31. doi: 10.1016/j.ejim.2013.08.706. Epub 2013 Sep 11. PMID: 24035704.

Tables

Table 1: Antihypertensive regimens in two groups

| GROUP 1 | N (513) | % |
|--------------------------------------|---------|------|
| Indapamide | 50 | 5.0 |
| ACE inh.+Thiazide | 197 | 19.7 |
| ARB inh.+Thiazide | 131 | 13.1 |
| ACE or ARB inh.+Thiazide+CCBs | 98 | 9.8 |
| Other combinations with diuretics | 37 | 3.7 |
| GROUP 2 | N (487) | |
| ACE inh. | 76 | 7.6 |
| ARB inh. | 48 | 4.8 |
| CCBs | 134 | 13.4 |
| ACE or ARB inh + CCBs | 142 | 14.2 |
| Beta blockers | 67 | 6.7 |
| Other combinations without diuretics | | 2 |
| Total | 1000 | 100 |

Table 2: Comparison of Biochemical Parameters in Two Groups

| | Group 1 | Group 2 p value |
|------------|---------|-----------------|
| BUN | 16,35 | 14,40 NS |
| CREATININE | 0,90 | 0,94 NS |
| SODIUM | 139,33 | 138,22 NS |
| POTASSIUM | 4,49 | 3,52 0,026 |
| CALCIUM | 9,52 | 9,61 NS |
| MAGNESIUM | 1,95 | 2,05 NS |
| URIC ACID | 5,51 | 5,23 NS |
| PHOSPORUS | 3,43 | 3,51 NS |

NS: Not significant; p value >0,05.

Table 3: The Relationship Between the Magnesium Levels and Other Measurements

| | | | Magnesium | |
|------------|--------|---|-----------|--------|
| | | | Low | Normal |
| BUN | Low | % | 1,6 | 1,0 |
| | Normal | % | 98,4 | 99 |
| Creatine | Low | % | 0,9 | 0,8 |
| | Normal | % | 99,1 | 99,2 |
| Sodium | Low | % | 14,0 | 10,2 |
| | Normal | % | 86,0 | 89,8 |
| Potassium | Low | % | 3,9 | 1,0 |
| | Normal | % | 84,5 | 84,0 |
| | High | % | 13,6 | 15,0 |
| Calcium | Low | % | 1,7 | 1,6 |
| | Normal | % | 98,3 | 98,4 |
| Uric acid | Low | % | 8,5 | 6,2 |
| | Normal | % | 66,7 | 69,5 |
| | High | % | 24,8 | 24,3 |
| Phosphorus | Low | % | 3,9 | 4,7 |
| | Normal | % | 96,1 | 95,3 |
| | | | 86 | |

Table 4: The Relationship Between the PPI Use and Hypomagnesemia

| | Diuretic group | | Nondiuretic group | | P value |
|--------------------------|------------------------|-----------------|------------------------|-----------------|---------|
| | The number of patients | Hypomg patients | The number of patients | Hypomg patients | |
| PPI users | 48 | 8 | 53 | 4 | 0.01 |
| Non-PPI users | 465 | 24 | 434 | 28 | 0.32 |
| Total number of patients | 513 | 36 | 487 | 33 | 0.34 |

Table 5: The Relationship Between the Number of Antihypertensives and Hypomagnesemia

| The number of antiHT drugs | Diuretic group | | Nondiuretic group | | P Value |
|----------------------------|------------------------|-----------------|------------------------|-----------------|---------|
| | The number of patients | Hypomg patients | The number of patients | Hypomg patients | |
| 1 | 87 | 5 | 92 | 5 | NS |
| 2 | 328 | 22 | 283 | 19 | NS |
| 3 and more | 98 | 9 | 112 | 9 | NS |
| Total number of patients | 513 | 36 | 487 | 33 | NS |

NS: Not significant; p value >0,05.

